Dr. Donna Smith is a Senior Consultant specializing in DFWP best practices and DOT Consulting. Dr. Smith was one of the principal authors and architects of the regulations for U.S. military, federal employees, and U.S. Department of Transportation (DOT) drug and alcohol testing programs. Dr. Smith has over 35 years’ experience and expertise in drug-free workplace program regulatory compliance. She is a nationally recognized expert in the areas of federal drug testing regulations, drug and alcohol testing procedures, drug and alcohol abuse awareness training for employees and managers, Medical Review Officer (MRO) procedures, drug-free workplace policy and procedures, and substance abuse prevention and rehabilitation. She has served on the American Society of Addiction Medicine (ASAM), the American College of Occupational and Environmental Medicine (ACOEM), the Substance Abuse and Mental Health Services Administration's (SAMHSA) Federal Drug Testing Advisory Board (DTAB), and the Board of Directors of the Substance Abuse Program Administrators Association (SAPAA).

Frank Bernard is a highly accomplished operations and compliance executive with a distinguished career at Walmart, the U.S. Department of Labor, and the U.S. Department of Housing and Urban Development. Frank is currently the Vice President of Ethics & Compliance at DISA Global Solutions.

Frank is responsible for translating DISA’s compliance vision into actionable strategies that support client performance, enhance program maturity, and create competitive compliance advantages. These strategies encompass the compliance subject matter areas of DOT and Transportation Compliance, Training and Education, Employee Screening, and Risk Management.

Nina M. French is the Managing Partner for the Current Consulting Group with over 26 years of experience in employee screening. Nina has experience in managing drug-free workplace operations, including product development, vendor management, medical review, client services, account management, marketing, and sales strategy. Her consulting emphasis is on helping screening companies streamline operations, define product portfolios, align core business goals, launch new products, increase revenue, and improve client retention. Nina's experience within the screening industry provides her with the expertise to consult with employers on program design, vendor selection, and best practices. Nina is widely published and speaks at over 40 events each year including client hosted educational trainings, webinars, SAPAA, DATIA, NAPBS, iHeart Radio, and SHRM.

Trial attorney, advisor, speaker focusing primarily on all aspects of drugs of abuse testing, representingand advising laboratories, collectors, employers, MROs and TPAs to ensure legal compliance andenhance workplace safety.

Richard Clay is a Vice President at Psychemedics Corporation, the world’s leading hair drug testing company, and has been with the company since 1992 pioneering hair testing in oil, chemical, and other industries. He has helped companies including BNSF, Shell, ConocoPhillips, Chevron, BP, and Valero sharpen insights into applicant and employee drug usage. He was also the driving force behind VECTOR, an application and service enabling owners and contractors to better detect and deter drug usage among workers. Prior to joining Psychemedics, Richard worked in the management consulting industry for 16 years.

David Porter, JD, CHC, CMQ/OE, CBRM, CPP-Champion. David Porter helps companies address risk. For nearly three decades, David has provided companies with advice to implement enterprise risk management systems that encompass multiple compliance areas, including quality, information security, business continuity, and safety. David’s approach centers on enterprise risk management delivery through integration with operational processes.

David is the Chief Compliance Officer for Clinical Reference Laboratory in Lenexa, Kansas. He also serves as an adjunct professor at Webster University. David holds a Juris Doctor from Notre Dame Law School, as well as certifications in quality, business continuity, business process management, and healthcare compliance.

Colin Woods has been in the drug testing industry since 2002 when he started with DISA. He has over 20 years of sales management experience, including four years with Kraft Foods. Colin is responsible for all aspects of the Sales Department including marketing, new business development, and consortium field operations. During his career with DISA, he has focused on growth throughout the energy and transportation industries. Colin is a graduate of the University of Kansas with a BBA in Business Administration.

A practicing emergency medicine physician and teacher at Highland General Hospital – one of the premier emergency medicine teaching facilities in the U.S. – Dr. Mike Lynn is also a clinical faculty member at the University of California, San Francisco. He is a former White House Fellow and Fulbright Scholar with an extensive background in public policy and public health, and he is a reserve deputy sheriff and a fully qualified and active SWAT team member. In addition, Dr. Lynn worked for 10 years as a venture capitalist specializing in medical devices and biotechnology. In this capacity, Dr. Lynn invested widely in emerging life science companies and served on multiple boards of directors. Dr. Lynn is currently CEO of Hound Labs, Inc., a scientific device company that has developed ultra-sensitive breath analysis technology that has been used to create the Hound marijuana and alcohol breathalyzer, which solves one of the biggest public safety problems associated with marijuana legalization: how to objectively determine if someone has recently used marijuana. Dr. Lynn lives near Oakland, CA with his wife, Jenny, their four children, and their Swiss mountain dog, Stanley.